Inhibitory effects of roxithromycin on tumor angiogenesis, growth and metastasis of mouse B16 melanoma cells

Clinical and Experimental Metastasis

Volumn 17, Issue 2, 1999, Pages 119-124

  Yatsunami, Jun ^a,c   Tsuruta, Nobuko ^a   Fukuno, Yuji ^c   Kawashima, Michihiro ^c   Taniguchi, Shun'ichiro ^b   Hayashi, Shin ichiro ^c  

^a KYUSHU UNIVERSITY   (Japan)

^b SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c SAGA UNIVERSITY   (Japan)

Author keywords

Angiogenesis; B16 melanoma; Macrolide; Metastasis; Roxithromycin; Tumor growth

Indexed keywords

FUMAGILLOL CHLOROACETYLCARBAMATE; MACROLIDE; ROXITHROMYCIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CELL INFILTRATION; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG INHIBITION; INTRAPERITONEAL DRUG ADMINISTRATION; LUNG METASTASIS; LUNG MODEL; MALE; MELANOMA B16; METASTASIS; METASTASIS INHIBITION; MICROVASCULATURE; MONONUCLEAR CELL; MOUSE; NONHUMAN; TUMOR GROWTH; TUMOR VASCULARIZATION;

AIR SACS; ANIMALS; ANTI-BACTERIAL AGENTS; ANTIBIOTICS, ANTINEOPLASTIC; CELL MOVEMENT; CYCLOHEXANES; DOSE-RESPONSE RELATIONSHIP, DRUG; LEUKOCYTES, MONONUCLEAR; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; MICE; NEOVASCULARIZATION, PATHOLOGIC; ROXITHROMYCIN; SESQUITERPENES; TUMOR CELLS, CULTURED;

EID: 0032765348     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006591805332     Document Type: Article

References (26)

1. Folkman J. Tumor angiogenesis. In: Mendelsohn J, Howley PM, Israel MA, Liotta LA (eds) The Molecular Basis of Cancer. Philadelphia: W. B. Saunders 1995; 206-32.
2. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1955; 1: 27-31.
3. Folkman J. Clinical applications of research on angiogenesis. N Engl J Med 1995; 333: 1757-63.
4. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA et al. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79: 315-28.
5. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G et al. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277-85.
6. Karp JE, Broder S. Molecular foundations of cancer: new targets for intervention. Nat Med 1995; 1: 309-20.
7. Agen C, Danesi R, Blandizzi C et al. Macrolide antibiotics as antiinflammatory agents: roxithromycin in an unexpected role. Agents Actions 1993; 38: 85-90.
8. Kadota J, Saito O, Kohno S et al. A mechanism of erythromycin treatment in patients with diffuse panbronchiolitis. Am Rev Respir Dis 1993; 147: 153-9.
9. Oishi K, Sonoda F, Kobayashi S et al. Role of interleukin-8 (IL-8) and an inhibitory effect of erythromycin on IL-8 release in the airways of patients with chronic airway diseases. Infect Immun 1994; 62: 4145-52.
10. Takizawa H, Desaki M, Ohtoshi T et al. Erythromycin suppresses interleukin-6 expression by human epithelial cells: a potential mechanism of its anti-inflammatory action. Biochem Biophys Res Commun 1995; 210: 781-6.
11. Mitsuyama T, Hidaka K, Furuno T et al. Neutrophil-induced endothelial cell damage: inhibition by a 14-membered ring macrolide through the action of nitric oxide. Int Arch Allergy Immunol 1997; 114: 111-5.
12. Yatsunami J, Tsuruta N, Wakamatsu K et al. Clarithromycin is a potent inhibitor of tumor induced angiogenesis. Res Exp Med (Berlin) 1997; 197: 189-97.
13. Yatsunami J, Tsuruta N, Hara N et al. Inhibition of tumor-induced angiogenesis by roxithromycin, a 14-membered ring macrolide antibiotic. Cancer Lett 1998 (in press).
14. Taniguchi S, Fujiki H, Kobayashi H et al. Effect of (-)-epigallocatechin gallate, the main constituent of green tea, on lung metastasis with mouse B16 melanoma cell lines. Cancer Lett 1992; 65: 51-4.
15. Yatsunami J, Tsuruta N, Ogata K et al. Interleukin-8 participates in angiogenesis in non-small cell, but not small cell carcinoma of the lung. Cancer Lett 1997; 120: 101-8.
16. Antoine N, Greimers R, Roanne MD et al. AGM-1470, a potent angiogenesis inhibitor, prevents the entry of normal but not transformed endothelial cells into the G1 phase of the cell cycle. Cancer Res 1994; 54: 2073-6.
17. Ingber D, Fujita T, Kishimoto S et al. Synthetic analogs of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 1998; 348: 555-7.
18. Yamaoka M, Yamamoto T, Masaki T et al. Inhibition of tumor growth and metastasis of rodent tumors by the angiogenesis inhibitor O-(chloroacetyl-carbamoyl)fumagillol (TNP-470; AGM-1470). Cancer Res 1993; 53: 4262-7.
19. Castronovo V, Belloti D. TNP-470 (AGM-1470): mechanisms of action and early clinical development. Eur J Cancer 1996; 32: 2520-7.
20. Sin N, Meng L, Wang MQW et al. The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MctAP-2. Proc Natl Acad Sci 1997; 94: 6099-103.
21. Konno S, Adachi M, Asano K et al. Influence of roxithromycin on cell-mediated immune responses. Life Sci 1992; 51: 107-12.
22. Yoshimura T, Kurita C, Yamazaki F et al. Effects of roxithromycin on proliferation of peripheral blood mononuclear cells and production of lipopolysaccharide-induced cytokines. Biol Pharm Bull 1995; 18: 876-81.
23. Hamada K, Kita E, Sawaki M et al. Antitumor effect of erythromycin in mice. Chemotherapy 1995; 41: 59-69.
24. Mikasa K, Sawaki M, Kita E et al. Significant survival benefit to patients with advanced non-small lung cancer from treatment with clarithromycin. Chemotherapy 1997; 43: 288-96.
25. Twardowski P, Gradishar WJ. Clinical trials of antiangiogenic agents. Curr Opin Oncol 1997; 9: 584-89.
26. Kusano S, Kadota J, Kohno S et al. Effects of roxithromycin on peripheral neutophil adhesion molecules in patients with chronic lower respiratory tract disease. Respiration 1995; 62(4): 217-22.